Karen Lewis - Apr 25, 2022 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role: Chief People Officer
Signature: /s/ David Watson, attorney-in-fact for Karen Lewis
Stock symbol: APLS
Transactions as of: Apr 25, 2022
Transactions value $: $1,624,298
Form type: 4
Date filed: 1/17/2023, 06:39 PM
Previous filing: Feb 1, 2022
Next filing: Jan 24, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	APLS	Common Stock	Other	$0	-1.25K	-5.33%	$0.00	22.2K	Apr 25, 2022	Direct	F1
transaction	APLS	Common Stock	Award	$0	+19.6K	+87.49%	$0.00	42.1K	Jan 12, 2023	Direct	F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	APLS	Stock Option (Right to Buy)	Other	$0	-7.5K	-100%	$0.00^*	0	Apr 25, 2022	Common Stock	7.5K	$44.90	Direct	F4, F5
transaction	APLS	Stock Option (Right to Buy)	Award	$1.62M	+30.8K		$52.66	30.8K	Jan 12, 2023	Common Stock	30.8K	$52.66	Direct	F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This represents the cancellation of a PSU awards granted on 01/28/2021 that was originally reported in table I upon grant. The performance metrics were not met.
F2	This represents a Restricted Stock Unit award granted 01/12/23 that vest annually from grant date over a four year period subject to continued service.
F3	This includes 125 shares from the 4/29/22 ESPP Purchase and 92 shares from the 10/31/22 ESPP Purchase.
F4	This represents the cancellation of a performance stock option granted on 01/28/2021. The performance metrics were not met.
F5	This stock option will vest as to 25% of the shares underlying the options on the first anniversary of the grant, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to the satisfaction of a specified performance condition and continued service.
F6	This represents a stock option award granted 01/12/2023 that vest over a four year period. 25% vest one year from grant date and the remaining 75% vest monthly thereafter subject to continued service.